Johnson & Johnson (NYSE:JNJ) Shares Bought by Rothschild Investment Corp IL

Posted by Defense World Staff on Mar 30th, 2023

Rothschild Investment Corp IL grew its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 107,940 shares of the company’s stock after buying an additional 1,218 shares during the quarter. Johnson & Johnson accounts for approximately 1.8% of Rothschild Investment Corp IL’s holdings, making the stock its 6th biggest holding. Rothschild Investment Corp IL’s holdings in Johnson & Johnson were worth $19,068,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in JNJ. DORCHESTER WEALTH MANAGEMENT Co grew its holdings in shares of Johnson & Johnson by 8.6% in the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after purchasing an additional 5,327 shares during the last quarter. Cantor Fitzgerald Investment Advisor L.P grew its holdings in shares of Johnson & Johnson by 88.9% in the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after purchasing an additional 82,429 shares during the last quarter. AMI Investment Management Inc. grew its holdings in shares of Johnson & Johnson by 8.8% in the 1st quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock worth $3,244,000 after purchasing an additional 1,475 shares during the last quarter. Equitable Holdings Inc. grew its holdings in shares of Johnson & Johnson by 4.9% in the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock worth $8,095,000 after purchasing an additional 2,119 shares during the last quarter. Finally, USS Investment Management Ltd boosted its position in Johnson & Johnson by 2.4% during the first quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock worth $152,488,000 after purchasing an additional 20,528 shares during the period. Institutional investors and hedge funds own 67.94% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the sale, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on JNJ shares. UBS Group started coverage on shares of Johnson & Johnson in a research report on Tuesday. They set a “neutral” rating and a $164.00 price objective for the company. Guggenheim started coverage on shares of Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 1st. Morgan Stanley lifted their target price on Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 25th. Finally, Atlantic Securities lifted their target price on Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a report on Wednesday, January 25th. Eight investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $173.67.

Johnson & Johnson Stock Up 1.0 %

JNJ stock opened at $153.31 on Thursday. The company has a market cap of $399.26 billion, a PE ratio of 22.75, a price-to-earnings-growth ratio of 2.63 and a beta of 0.54. The business has a 50-day simple moving average of $158.62 and a 200 day simple moving average of $167.29. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $186.69. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, topping the consensus estimate of $2.22 by $0.13. The firm had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The business’s quarterly revenue was down 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.13 earnings per share. Sell-side analysts anticipate that Johnson & Johnson will post 10.5 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were issued a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a dividend yield of 2.95%. The ex-dividend date was Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 67.06%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.